|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2002-7-31
|
|
pubmed:abstractText |
Gemcitabine is generally considered to constitute first-line therapy for pancreatic cancer. To determine whether the addition of fluorouracil (5-FU) improves on the results from single-agent gemcitabine, the Eastern Cooperative Oncology Group (ECOG) compared gemcitabine plus bolus 5-FU with gemcitabine alone for patients with advanced pancreatic carcinoma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3270-5
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:12149301-Adult,
pubmed-meshheading:12149301-Aged,
pubmed-meshheading:12149301-Antimetabolites, Antineoplastic,
pubmed-meshheading:12149301-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12149301-Deoxycytidine,
pubmed-meshheading:12149301-Disease-Free Survival,
pubmed-meshheading:12149301-Female,
pubmed-meshheading:12149301-Fluorouracil,
pubmed-meshheading:12149301-Humans,
pubmed-meshheading:12149301-Male,
pubmed-meshheading:12149301-Middle Aged,
pubmed-meshheading:12149301-Pancreatic Neoplasms,
pubmed-meshheading:12149301-Proportional Hazards Models,
pubmed-meshheading:12149301-Statistics, Nonparametric,
pubmed-meshheading:12149301-Survival Analysis,
pubmed-meshheading:12149301-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
|
|
pubmed:affiliation |
Vanderbilt University, 777 Preston Research Building, Nashville, TN 37232-6307, USA. jorden.berlin@mcmail.vanderbilt.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Clinical Trial, Phase III
|
